Schrodinger (SDGR) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Schrodinger (SDGR) has outperformed Xeris Biopharma (XERS) over the past year, gaining 27.4% versus a gain of 24.3%. Over five years, XERS leads with a +409.5% price change compared with -52.3% for SDGR. Schrodinger is the larger company by market cap ($2.05 billion vs $1.90 billion), about 1.1 times the size, while Xeris Biopharma is growing revenue faster (+43.7% vs +23.3%).
Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -40.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | XERS |
|---|---|---|
| Share price | $27.35 | $10.44 |
| Market cap | $2.05B | $1.90B |
| 1-day change | +3.64% | +2.45% |
| YTD return | +47.60% | +29.81% |
| 1-year return | +27.36% | +24.27% |
| 5-year return | -52.33% | +409.50% |
| Forward P/E | — | 28.22 |
| EPS (TTM) | $-0.74 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $255.87M | $291.85M |
| Revenue growth (YoY) | +23.29% | +43.72% |
| Net income (latest FY) | $-103.27M | $554.00K |
| Gross margin | 55.74% | 85.41% |
| Operating margin | -65.23% | 8.53% |
| Net margin | -40.36% | 0.19% |
| 52-week high | $33.78 | $11.33 |
| 52-week low | $10.95 | $5.25 |
| Distance from 52-week high | -19.03% | -7.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -21.65% | +23.18% |
| Average volume | 1.78M | 2.17M |
| Shares outstanding | 65.64M | 182.32M |
| Employees | 850 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -40.4 cents for Schrodinger.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +23.29%).
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
SDGR vs XERS FAQ
Which is bigger, Schrodinger or Xeris Biopharma?
Schrodinger (SDGR) is larger, with a market capitalization of $2.05B compared with $1.90B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, SDGR or XERS?
SDGR returned +27.36% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.